| Abstrakt: |
A recent study conducted by researchers at Peking University in Beijing, China, explored the potential of a subcutaneous PD-L1 antibody called ASC22 in treating chronic hepatitis B (CHB) patients. The study involved a 24-week treatment with ASC22 or a placebo in two cohorts of CHB patients on nucleos(t)ide analogs (NAs), followed by a 24-week follow-up period. The results showed that the subcutaneous administration of ASC22 was safe and well-tolerated in virally suppressed CHB patients on NAs and led to a decline in hepatitis B surface antigen (HBsAg) levels, particularly in patients with HBsAg levels below 100 IU/mL. The study was supported by Ascletis BioScience and has been peer-reviewed. [Extracted from the article] |
